Beam Therapeutics Inc (NASDAQ: BEAM) is -9.99% lower on its value in year-to-date trading and has touched a low of $16.95 and a high of $49.50 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BEAM stock was last observed hovering at around $24.77 in the last trading session, with the day’s loss setting it -0.27%.
Currently trading at $24.50, the stock is -2.31% and -6.64% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.82 million and changing -1.09% at the moment leaves the stock -10.16% off its SMA200. BEAM registered 6.48% gain for a year compared to 6-month loss of -26.25%. The firm has a 50-day simple moving average (SMA 50) of $26.1864 and a 200-day simple moving average (SMA200) of $27.249624.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -9.63% gain in the last 1 month and extending the period to 3 months gives it a -1.37%, and is -3.96% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.74% over the week and 5.03% over the month.
Beam Therapeutics Inc (BEAM) has around 436 employees, a market worth around $2.02B and $352.57M in sales. Profit margin for the company is -40.56%. Distance from 52-week low is 44.54% and -50.51% from its 52-week high. The company has generated returns on investments over the last 12 months (-14.21%).
The EPS is expected to shrink by -173.40% this year
323.0 institutions hold shares in Beam Therapeutics Inc (BEAM), with institutional investors hold 95.17% of the company’s shares. The shares outstanding are 81.63M, and float is at 71.60M with Short Float at 15.31%. Institutions hold 93.75% of the Float.
The top institutional shareholder in the company is FARALLON CAPITAL MANAGEMENT LLC with over 7.91 million shares valued at $185.4 million. The investor’s holdings represent 9.6857 of the BEAM Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 7.9 million shares valued at $185.11 million to account for 9.6701 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 7.63 million shares representing 9.3446 and valued at over $178.87 million, while ARK INVESTMENT MANAGEMENT LLC holds 9.3345 of the shares totaling 7.63 million with a market value of $178.68 million.
Beam Therapeutics Inc (BEAM) Insider Activity
The most recent transaction is an insider sale by Simon Amy, the company’s Chief Medical Officer. SEC filings show that Simon Amy sold 748 shares of the company’s common stock on Jul 02 ’24 at a price of $22.95 per share for a total of $17167.0. Following the sale, the insider now owns 68805.0 shares.
Beam Therapeutics Inc disclosed in a document filed with the SEC on Jul 01 ’24 that Simon Amy (Chief Medical Officer) sold a total of 502 shares of the company’s common stock. The trade occurred on Jul 01 ’24 and was made at $23.76 per share for $11928.0. Following the transaction, the insider now directly holds 69553.0 shares of the BEAM stock.
Still, SEC filings show that on Jun 27 ’24, Evans John M. (CEO) disposed off 60,000 shares at an average price of $24.50 for $1.47 million. The insider now directly holds 998,343 shares of Beam Therapeutics Inc (BEAM).
